Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-18Clinical Trial Update: Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors [Phase 2]
A Phase 2 trial evaluating asciminib versus best available therapy in chronic myeloid leukemia in chronic phase patients previously treated …
-
CLINICAL_TRIALS trial_result · 2025-04-18Clinical Trial Update: Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
This clinical trial update reports on front-line nilotinib treatment for patients with chronic phase BCR-ABL positive chronic myeloid leukem…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial [Phase 2]
Phase 2 trial evaluating fecal microbiota transplantation before allogeneic stem cell transplant; recruitment is ongoing across multiple hem…
-
FDA approval · 2025-04-14FDA Approved: IMATINIB MESYLATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' imatinib mesylate as an original (ANDA) generic product.
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia [NA]
A recruiting clinical trial at Centre Hospitalier Universitaire de Saint-Étienne investigating drug interactions, phytotherapy, and targeted…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [Phase 2]
A Phase 2 trial evaluating α/β+-T lymphocyte-depleted donor grafts from HLA-mismatched donors in multiple hematologic malignancies was termi…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation [Phase 2]
Phase 2 clinical trial update for patients with chronic myeloid leukemia or acute lymphoblastic leukemia who failed prior TKIs or have the T…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response [Phase 2]
Phase 2 trial evaluating discontinuation of imatinib in chronic myeloid leukemia patients with deep molecular response; the study has comple…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: Asciminib Treatment Optimization in ≥ 3rd Line CML-CP [Phase 3]
A Phase 3 trial evaluating asciminib for treatment optimization in patients with chronic myeloid leukemia in chronic phase who are on ≥ thir…
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia
A clinical trial is currently recruiting to compare the efficacy and safety of Carcemia, a generic imatinib, with Glivec in the real-world m…
-
FDA approval · 2025-03-20FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate (Teva) under an ANDA, authorizing continued regulatory approval for this gener…
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality [Phase 3]
A Phase 3 trial evaluating a cardiovascular preventive strategy in chronic myeloid leukemia has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia [Phase 2]
This Phase 2 trial examines de-escalation and stopping treatment with imatinib, nilotinib, or dasatinib (Sprycel) in chronic myeloid leukemi…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP [Phase 3]
Phase 3 clinical trial update comparing oral asciminib with other tyrosine kinase inhibitors in adults with newly diagnosed Philadelphia chr…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP [Phase 3]
Phase 3 trial comparing oral asciminib to other TKIs in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemi…
-
CLINICAL_TRIALS research · 2025-03-10Clinical Trial Update: Venetoclax After TKI to Target Persisting Stem Cells in CML [Phase 2]
Phase 2 clinical trial evaluating venetoclax after tyrosine kinase inhibitors to eradicate persisting stem cells in chronic myeloid leukemia…
-
CLINICAL_TRIALS other · 2025-03-10Clinical Trial Update: Frontline Asciminib Combination in Chronic Phase CML [Phase 2]
A Phase 2 trial evaluating frontline asciminib in chronic phase chronic myeloid leukemia is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
-
CLINICAL_TRIALS research · 2025-03-07Clinical Trial Update: Evaluation of CD47, "Do Not Eat Me" Signal Expression in Chronic Myeloid Leukemia
Clinical trial update investigating expression of the CD47 'do not eat me' signal in chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
This completed clinical trial evaluated myeloablative hematopoietic progenitor cell transplantation in pediatric patients with chronic myelo…
-
CLINICAL_TRIALS trial_result · 2025-03-03Clinical Trial Update: A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase [Phase 2]
A Phase 2 pivotal study evaluating HQP1351 in patients with chronic myeloid leukemia in chronic phase has completed.
-
FDA approval · 2025-03-03FDA Approved: DASATINIB — Original Application (Biocon Pharma Inc.)
FDA approves Biocon Pharma Inc.'s original application for dasatinib (generic) to treat certain leukemias, marking the availability of a gen…
-
FDA approval · 2025-03-03FDA Approved: DASATINIB — Original Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved an original application for dasatinib from Zydus Pharmaceuticals USA Inc., enabling a generic version of the cancer drug. D…
-
FDA approval · 2025-03-03FDA Approved: DASATINIB — Original Application (Dr.Reddys Laboratories Inc)
FDA approved the original application for dasatinib by Dr. Reddy's Laboratories Inc, providing a generic version of dasatinib for leukemias.…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients [Phase 1]
Phase 1 clinical trial update for TGRX-678 in Chinese patients with chronic myeloid leukemia; trial is currently active but not recruiting.